KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cme Group (CME) EBITDA: 2009-2024

Historic EBITDA for Cme Group (CME) over the last 16 years, with Dec 2024 value amounting to $3.9 billion.

  • Cme Group's EBITDA fell 5.07% to $999.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 billion, marking a year-over-year increase of 7.71%. This contributed to the annual value of $3.9 billion for FY2024, which is 14.43% up from last year.
  • Per Cme Group's latest filing, its EBITDA stood at $3.9 billion for FY2024, which was up 14.43% from $3.4 billion recorded in FY2023.
  • In the past 5 years, Cme Group's EBITDA ranged from a high of $3.9 billion in FY2024 and a low of $2.6 billion during FY2020.
  • Over the past 3 years, Cme Group's median EBITDA value was $3.4 billion (recorded in 2023), while the average stood at $3.5 billion.
  • Data for Cme Group's EBITDA shows a peak YoY climbed of 14.43% (in 2024) over the last 5 years.
  • Cme Group's EBITDA (Yearly) stood at $2.6 billion in 2020, then grew by 0.30% to $2.6 billion in 2021, then climbed by 14.01% to $3.0 billion in 2022, then rose by 13.92% to $3.4 billion in 2023, then grew by 14.43% to $3.9 billion in 2024.